Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.67 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desomorphine SCHEMBL24969 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Desomorphine SCHEMBL11630127 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Desomorphine SCHEMBL12720171 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Desomorphine SCHEMBL46252 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL15866691 | 0.94 | OPRD1 (0.60) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL16866227 | 0.94 | OPRD1 (0.60) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL11631069 | 0.85 | OPRM1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2 | |
| SCHEMBL21202077 | 0.85 | OPRM1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2 | |
| SCHEMBL21202024 | 0.85 | OPRM1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2 | |
| SCHEMBL11631074 | 0.85 | OPRM1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150182462-A1 | Opioid-Containing Oral Pharmaceutical Compositions and Methods | UPSHER-SMITH LABORATORIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8362029-B2 | Opioid-containing oral pharmaceutical compositions and methods | UPSHER-SMITH LABORATORIES, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362029-B2 | Opioid-containing oral pharmaceutical compositions and methods | UPSHER-SMITH LABORATORIES, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110275658-A1 | OPIOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITIONS AND METHODS | UPSHER-SMITH LABORATORIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275658-A1 | OPIOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITIONS AND METHODS | OPRK1, OPRM1, OPRL1 | OPRD1 4/4885OPRM1 2/4885OPRK1 1/4885 |
| US-20150182462-A1 | Opioid-Containing Oral Pharmaceutical Compositions and Methods | OPRK1, OPRM1, OPRL1 | OPRD1 4/4885OPRM1 2/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.